September 18, 2025 — Leads & Copy — A joint venture and license agreement between Avant Technologies Inc. and Austrianova will establish Klothonova, Inc., a new Nevada corporation focused on cell-based therapies utilizing encapsulated Klotho-producing cells. The global cell therapy market is expected to reach $44.39 billion by 2034, expanding at a CAGR of 22.69%.
Klothonova will leverage Austrianova’s cell-encapsulation technology to develop and commercialize treatments for Alzheimer’s, heart disease, cancer, kidney disease, and other age-related conditions. Avant will provide capital and resources to support Klothonova’s operations. The company will focus on treatments through the overexpression of the Klotho protein, encapsulated using Austrianova’s technology.
Chris Winter, CEO at Avant Technologies, stated that the partnership with Austrianova will advance transformative healthcare solutions. Brian Salmons, CEO of Austrianova, added that the joint venture will accelerate the development of Klotho-based therapies.
Other developments include Renalytix plc partnering with Tempus AI, Inc. to expand access to kidneyintelX.dkd prognostic blood testing. CRISPR Therapeutics will present Phase 1 clinical data on CTX310 for cardiovascular and cardiometabolic disease at the American Heart Association Scientific Sessions 2025. BioNTech SE and Bristol Myers Squibb Company presented interim data on pumitamig plus chemotherapy for patients with extensive-stage small cell lung cancer at the IASLC 2025 World Conference on Lung Cancer.
Media Contact: editor@marketnewsupdates.com – +1(561)325-8757
Source: MarketNewsUpdates Source: MarketNewsUpdates
